Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Bexarotene | |
| Synonyms |
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid 3-methyl TTNEB BEXAROTENE Bexarotene LGD1069 Targretin bexarotene |
|
| Definitions |
A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1635 |
|
| Accepted_Therapeutic_Use_For |
Oral or topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).
|
|
| ALT_DEFINITION |
A drug used to treat skin problems caused by cutaneous T-cell lymphoma that have not gotten better after other treatment. It is also being studied in the treatment of other types of cancer. Bexarotene is a type of retinoid.
|
|
| CAS_Registry |
153559-49-0
|
|
| CHEBI_ID |
CHEBI:50859
|
|
| Chemical_Formula |
C24H28O2
|
|
| code |
C1635
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)
|
|
| Display_Name |
Bexarotene
|
|
| FDA_UNII_Code |
A61RXM4375
|
|
| FULL_SYN |
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid 3-methyl TTNEB BEXAROTENE Bexarotene LGD1069 Targretin bexarotene
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Bexarotene
|
|
| Legacy Concept Name |
Bexarotene
|
|
| Maps_To |
Bexarotene
|
|
| NCI_Drug_Dictionary_ID |
42117
|
|
| PDQ_Closed_Trial_Search_ID |
42117
|
|
| PDQ_Open_Trial_Search_ID |
42117
|
|
| Preferred_Name |
Bexarotene
|
|
| prefixIRI |
Thesaurus:C1635
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C0765273
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |